CALCBC: NORML Alert: Project CBD Raises Concerns About RE Online Marketed CBD oils
From Paul Armentano of NORML:
A new report by Project CBD raises numerous questions re the safety, credibility, and legality of mass-marketed CBD oil products, such as those available on the Internet from marketplaces like Amazon.com.
You can read the full report here:
Testing of several of these products have identified significant quantities of toxic solvents;
Testing of several of these products have found negligible quantities of CBD;
Claims that these products obtain their CBD from legal industrial hemp crops in other countries are most likely disingenuous:
„CBD is not produced or pressed from hemp seeds. Cannabidiol can only be extracted from the flower, leaves, and, to a very minor extent, the stalk of the hemp plant.‰
„[T]hose who say they‚re extracting CBD only from the stalk of industrial hemp are almost certainly being disingenuous. Either they are bluffing to make it appear as though they are operating legally˜or they are extracting the oil in a way that makes a dangerous product more likely. Extracting cannabidiol from hemp stalk ups the risk of concentrated, bio-accumulated contaminants because so much plant matter has to be processed to get any CBD.‰
Claims that these products are Œlegal‚ in all 50 states is false:
„Contrary to what Medical Marijuana Inc. claims, CBD-infused „hemp oil‰ is not federally legal in all 50 states. In some lab tests, RSHO products were found to have more than the legal limit of THC. Moreover, cannabidiol in any form is still a Schedule One substance, according to the DEA and FDA.‰
Below is a press release highlighting the new paper:
Miracle Drug Or Poison? One Company‚s Sketchy Saga
By Martin Lee
Project CBD feels strongly that this report should not be taken as justification to attack the medical marijuana community or impose ever-more capricious restrictions on patients and providers.
Nor do we wish to cast aspersions on well-intentioned companies that are working with industrial hemp to create CBD-rich products. We believe that industrial hemp is not an optimal source of CBD, but it can be a viable source of CBD if certain hemp cultivars are grown organically in good soil and safe extraction and refinement methods are employed.
Currently under federal law industrial hemp grown abroad is legal for importation and sale in the United States as long as the hemp product contains 0.3 percent THC or less and is derived from the seed or stalk of the plant, not from the leaves and flowers. But CBD can‚t be extracted from hempseed. This means that hemp stalk, which contains little CBD, might be the only legal source of cannabidiol from foreign-grown industrial hemp.
Sourcing CBD from industrial hemp stalk is inherently problematic because a huge amount of plant material is required for sufficient oil extraction. Hemp is a bioaccumulator; it sucks up contaminants from the soil. Hemp‚s phyto-remedial properties increase the likelihood that heavy metals and other poisons will be extracted and concentrated along with a tiny amount of CBD from the stalk.
Project CBD maintains that federal law should be changed to facilitate CBD production from the most prolific natural source of cannabidiol available ˜ CBD-rich cannabis with little THC. Practically speaking, this would entail de-scheduling the whole plant, not just a single compound or single strain.
For the first time since the late 1950s, researchers in the United States were allowed to grow industrial hemp legally in 2014. There‚s no doubt that the surge of national interest in CBD has been a key factor in catalyzing the domestic rebirth of industrial hemp. CBD is also where industrial hemp intersects with the great laboratory experiment in democracy known as medical marijuana.
Given the enormous therapeutic potential of whole plant cannabidiol, it‚s imperative to implement sensible regulations for CBD-rich products in accordance with safety standards that apply to other medicinal herbs. All cannabis oil products should be lab tested for contaminants and labeled accurately for content. If tainted products are discovered, they should be recalled without delay. Relevant quality control standards are delineated in the American Herbal Pharmacopoeia‚s recent monograph on cannabis. These guidelines should be adopted by state regulators and welcomed by the medical marijuana community.
Read the full report.
Martin A. Lee is Director of Project CBD